Bergman L et al. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres’ ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen. Lancet 2000;356(9233):881-7. Abstract
Choi S et al. Risk of endometrial cancer and frequencies of invasion endometrial procedures in young breast cancer survivors treated with tamoxifen: A nationwide study. Front Oncol 2021;11:636378. Abstract
Cobb L, Gershenson D. Novel therapeutics in low-grade serous ovarian cancer. Int J Gynecol Cancer 2023;33(3):377-84. Abstract
DiSilvestro P et al. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: The SOLO1/GOG 3004 trial. J Clin Oncol 2023;41(3):609-17. Abstract
González-Martín A et al. Progression-free survival and safety at 3.5years of follow-up: Results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer. Eur J Cancer 2023;189:112908. Abstract
González-Martín A et al. PRIMA/ENGOT-OV26/GOG-3012 study: Updated long-term PFS and safety. IGCS 2022;Abstract S005/1753.
Harter P et al. Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial. ASCO 2023;Abstract LBA5506.
Jones JR et al. Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI trial. EClinicalMedicine 2023;62:102099. Abstract
Jones JR et al. Second malignancies in the context of lenalidomide treatment: An analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Blood Cancer J 2016;6(12):e506. Abstract
Konstantinopoulos PA et al. EPIK-O/ENGOT-OV61: Alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study). Future Oncol 2022;18(31):3481-92. Abstract
Li N et al. Treatment with niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: A phase 3 randomized clinical trial. JAMA Oncol 2023;9(9):1230-37. Abstract
Liu JF et al. An open-label phase 2 study of dostarlimab (TSR-042), bevacizumab (bev), and niraparib combination in patients (pts) with platinum-resistant ovarian cancer (PROC): Cohort A of the OPAL trial. SGO 2021;Abstract 10415.
Madariaga A et al. Novel therapies leading to a new landscape in gynecologic tumors. Int J Gynecol Cancer 2023;33(3):321-2. Abstract
Meric-Bernstam F et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol 2023;[Online ahead of print]. Abstract
Pina PS, Lheureux S. Overcoming PARP inhibitor resistance in ovarian cancer. Int J Gynecol Cancer 2023;33(3):364-76. Abstract
Randall LM et al. MOONSTAR/GOG-3032: Interim analysis of a phase 2 study of niraparib + dostarlimab in patients (pts) with platinum-resistant ovarian cancer (PROC). ASCO 2022;Abstract 5573.
Ray-Coquard I et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: Final overall survival results from the PAOLA-1/ENGOT-ov25 trial. Ann Oncol 2023;34(8):681-92. Abstract
Redondo A et al. Controversies in the treatment of advanced ovarian cancer in the PARP inhibitors era: A Delphi consensus. J Gynecol Oncol 2023;34(5):e57. Abstract
Stewart J et al. New therapies for clear cell ovarian carcinoma. Int J Gyne Cancer 2023;33(3):385-93. Abstract